Immunoprophylaxis using intravenous Rh immune globulin should be standard practice when selected D-negative patients are transfused with D-positive random donor platelets

Immunohematology

Volumn 14, Issue 4, 1998, Pages 133-137

  Ewing, C A ^a   Rumsey, D H ^a   Langberg, A F ^a   Sandler, S G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti D; blood transfusion standards; platelet transfusion; Rh alloimmunization; RhIG

Indexed keywords

RHESUS D ANTIBODY; THROMBOCYTE CONCENTRATE;

AGED; ALLOIMMUNIZATION; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG INDICATION; FEMALE; HUMAN; IMMUNOPROPHYLAXIS; INTRAVENOUS DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHESUS IMMUNIZATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0031741476     PISSN: 0894203X     EISSN: 19303955     Source Type: Journal    
DOI: 10.21307/immunohematology-2019-680     Document Type: Article

References (12)

1. McLeod BC, Piehl MR, Sassetti RJ. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 1990; 59:185–9.
2. Hong F, Ruiz R, Price H, et al. Safety profile of WinRho anti-D. Semin Hematol 1998;35(Suppl):9–13.
3. Package insert: Rho (D) Immune Globulin Intravenous (Human)/WinRho SDF™ Cangene Corporation, Winnipeg, Canada. Distributed by Nabi, Boca Raton, FL.
4. Standards for Blood Banks and Transfusion Services. 16th ed. Bethesda, MD: American Association of Blood Banks, 1994.
5. Standards for Blood Banks and Transfusion Services. 18th ed.Bethesda,MD: American Association of Blood Banks, 1996.
6. Hartwell EA. Use of Rh immune globulin/ASCP practice parameter. Am J Clin Pathol 1998;110:281–92.
7. Urbaniak SJ. Consensus conference on anti-D prophylaxis, April 7 & 8,1997:final consensus statement, Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynecologists. Transfusion 1998;38:97–9.
8. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford, England: Blackwell Science, 1997:175.
9. McGinniss MH, Bronson WR, Freireich E, Kliman A. Formation of red cell antibodies in response to platelet transfusions.Transfusion 1963;3:426.
10. Goldfinger D, McGinniss MH. Rh-incompatible platelet transfusions—risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971;284:942–4.
11. Lichtiger B, Surgeon J, Rhorer S. Rh-incompatible platelet transfusion therapy in cancer patients. Vox Sang 1983;45:139–43.
12. Lichtiger B, Hester JP.Transfusion of Rh-incompatible blood components to cancer patients. Haematologia 1986;19:81–8.